NAV

Phenprobamate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Phenprobamate is a skeletal muscle relaxant indicated in the treatment of pain caused by muscle spasms.

Generic Name
Phenprobamate
DrugBank Accession Number
DB13354
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 179.219
Monoisotopic: 179.094628663
Chemical Formula
C10H13NO2
Synonyms
  • Phenprobamate
External IDs
  • MH-532
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatPainCombination Product in combination with: Acetaminophen (DB00316)••••••••••••••••••
Treatment ofPain••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Phenprobamate.
AcetazolamideThe risk or severity of CNS depression can be increased when Acetazolamide is combined with Phenprobamate.
AcetophenazineThe risk or severity of CNS depression can be increased when Acetophenazine is combined with Phenprobamate.
AgomelatineThe risk or severity of CNS depression can be increased when Agomelatine is combined with Phenprobamate.
AlfentanilThe risk or severity of CNS depression can be increased when Alfentanil is combined with Phenprobamate.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
KUIFLEX 200 MG/200 MG FİLM KAPLI TABLET, 40 ADETPhenprobamate (200 mg) + Acetaminophen (200 mg)Tablet, film coatedOralABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş.1989-02-03Not applicableTurkey flag
KUILIL 200 MG/200 MG FİLM TABLET, 40 TABLETPhenprobamate (200 mg) + Acetaminophen (200 mg)Tablet, film coatedOralEXELTIS İLAÇ SAN. VE TİC. A.Ş.1964-10-05Not applicableTurkey flag

Categories

ATC Codes
M03BA71 — Phenprobamate, combinations with psycholepticsM03BA51 — Phenprobamate, combinations excl. psycholepticsM03BA01 — Phenprobamate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Carboximidic acids and derivatives / Organopnictogen compounds / Organooxygen compounds / Imines / Hydrocarbon derivatives
Substituents
Aromatic homomonocyclic compound / Carboximidic acid derivative / Hydrocarbon derivative / Imine / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
UJZ473TPS0
CAS number
673-31-4
InChI Key
CAMYKONBWHRPDD-UHFFFAOYSA-N
InChI
InChI=1S/C10H13NO2/c11-10(12)13-8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H2,11,12)
IUPAC Name
3-phenylpropyl carbamate
SMILES
NC(=O)OCCCC1=CC=CC=C1

References

General References
  1. TITCK Product Information: Gamaflex (phenprobamate) oral tablet [Link]
  2. TITCK Product Information: Kuiflex (phenprobamate/acetaminophen) oral tablets [Link]
ChemSpider
4606
BindingDB
66801
ChEBI
31992
ChEMBL
CHEMBL1079576
ZINC
ZINC000001676954
Wikipedia
Phenprobamate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, coatedOral400 mg
Tablet, film coatedOral400 mg
Tablet, film coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.514 mg/mLALOGPS
logP1.77ALOGPS
logP2.05Chemaxon
logS-2.5ALOGPS
pKa (Strongest Acidic)15.69Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count1Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area52.32 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity50.06 m3·mol-1Chemaxon
Polarizability19.58 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014l-6900000000-2cb3269745a3b29bcd27
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-2900000000-42b2fbc10c0798fb71d8
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-48f5aa5980ad3fcbaa97
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-066u-6900000000-fde769f7068cef55ec13
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-1476c6715380e4cac656
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-9100000000-d9ea58bf82587767ee44
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-146.5573959
predicted
DarkChem Lite v0.1.0
[M-H]-146.5189959
predicted
DarkChem Lite v0.1.0
[M-H]-134.99327
predicted
DeepCCS 1.0 (2019)
[M+H]+145.1384959
predicted
DarkChem Lite v0.1.0
[M+H]+146.0922959
predicted
DarkChem Lite v0.1.0
[M+H]+138.36641
predicted
DeepCCS 1.0 (2019)
[M+Na]+146.4688959
predicted
DarkChem Lite v0.1.0
[M+Na]+146.5787959
predicted
DarkChem Lite v0.1.0
[M+Na]+147.73741
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:40 / Updated at June 02, 2021 20:04